581 related articles for article (PubMed ID: 8558937)
1. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
2. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
3. Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
Kim HS; Min YD; Choi CH
Biochem Biophys Res Commun; 2001 Apr; 283(1):64-71. PubMed ID: 11322768
[TBL] [Abstract][Full Text] [Related]
4. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia.
Hart SM; Ganeshaguru K; Hoffbrand AV; Prentice HG; Mehta AB
Leukemia; 1994 Dec; 8(12):2163-8. PubMed ID: 7808005
[TBL] [Abstract][Full Text] [Related]
5. Expression of the human major vault protein LRP in acute myeloid leukemia.
Hart SM; Ganeshaguru K; Scheper RJ; Prentice HG; Hoffbrand AV; Mehta AB
Exp Hematol; 1997 Nov; 25(12):1227-32. PubMed ID: 9357965
[TBL] [Abstract][Full Text] [Related]
6. Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
Köhler T; Leiblein S; Borchert S; Eller J; Rost AK; Lassner D; Krahl R; Helbig W; Wagner O; Remke H
Adv Exp Med Biol; 1999; 457():177-85. PubMed ID: 10500792
[TBL] [Abstract][Full Text] [Related]
7. MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.
Beck J; Niethammer D; Gekeler V
Leukemia; 1996 Jul; 10 Suppl 3():S39-S45. PubMed ID: 8656699
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
Choi CH; Ling V
Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
[TBL] [Abstract][Full Text] [Related]
11. Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation.
Xu D; Knaust E; Pisa P; Palucka K; Lundeberg J; Areström I; Peterson C; Gruber A
Br J Haematol; 1996 Mar; 92(4):847-54. PubMed ID: 8616077
[TBL] [Abstract][Full Text] [Related]
12. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
Nasilowska-Adamska B; Solarska I; Paluszewska M; Malinowska I; Jedrzejczak WW; Warzocha K
Ann Hematol; 2014 Apr; 93(4):577-93. PubMed ID: 24030729
[TBL] [Abstract][Full Text] [Related]
14. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
[TBL] [Abstract][Full Text] [Related]
16. Amplification and expression of the ABC transporters ARA and MRP in a series of multidrug-resistant leukaemia cell sublines.
O'Neill GM; Peters GB; Harvie RM; MacKenzie HB; Henness S; Davey RA
Br J Cancer; 1998 Jun; 77(12):2076-80. PubMed ID: 9649117
[TBL] [Abstract][Full Text] [Related]
17. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia.
Zhou DC; Zittoun R; Marie JP
Leukemia; 1995 Oct; 9(10):1661-6. PubMed ID: 7564506
[TBL] [Abstract][Full Text] [Related]
18. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
[TBL] [Abstract][Full Text] [Related]
19. [The clinical significance of multidrug resistance associated protein(MRP) gene expression in acute leukemia].
Wang F; Dong Z; Luo J
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):63-6. PubMed ID: 10921103
[TBL] [Abstract][Full Text] [Related]
20. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
